Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome.
Saved in:
| Title: | Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. |
|---|---|
| Authors: | Elghawy O; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Sussman JH; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Yang AG; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Thomas CJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Carter JS; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Landsburg DJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Svoboda J; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Kim E; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Rook AH; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Chung J; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Plastaras JP; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., LaRiviere M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., Hubbeling H; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., Chelius M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., Nasta SD; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Chong EA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Barta SK; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia. |
| Source: | JAMA dermatology [JAMA Dermatol] 2025 Jun 01; Vol. 161 (6), pp. 656-658. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6084 |
|---|---|
| DOI: | 10.1001/jamadermatol.2025.0251 |
